Urologie pro praxi 5/2003
Současný pohled na metastázující karcinom ledviny z hlediska přežití v závislosti na druhu terapie
Present view on avanced renal carcinoma from the perspective of survival dependent on type of the therapy Advanced renal cell carcinoma is a disease that is highly resistant to systemic therapy and is difficult to treat. Nephrectomy should be seriously considered in patients who present with metastatic disease prior to systemic therapy, and surgery remains a reasonable option in patients who present with resectable metastases. Numerous studies with many different treatment modalities, including chemotherapy, immunotherapy and radiation therapy, have failed to consistently benefit patients, with no single agent or combination therapy showing a reproducible response proportion of 20 % or higher. Interleukin-2 a interferon-alfa-based therapies remain the most commonly used agents to treat patients with advanced disease, demonstrating low but reproducible response proportions in the 10 % to 20 % range, with durable responses of 5 % or less. Key words: metastatic renal cell carcinoma, nephrectomy, immunotherapy.